Yescarta

Approved Conditions

Yescarta is a chimeric antigen receptor (CAR) T-cell therapy. It is used to treat adults with specific types of large B-cell lymphoma, including:

• Diffuse large B-cell lymphoma (DLBCL)
• Primary mediastinal large B-cell lymphoma
• High-grade B-cell lymphoma
• DLBCL arising from follicular lymphoma

In these cases, Yescarta is typically used when the cancer has not responded to initial chemoimmunotherapy or has returned within 12 months of that treatment. It is also used for patients whose cancer has returned or failed to respond after at least two other types of systemic treatment.

Follicular Lymphoma

Yescarta is also used for adults with follicular lymphoma that has returned or failed to respond after two or more previous lines of systemic therapy.

Limitations

Yescarta is not approved for the treatment of primary central nervous system lymphoma.

The CAR T-Cell Process

Yescarta works by reprogramming a patient's T cells, which are a type of white blood cell responsible for fighting infections and diseases. The process involves several steps:

• Collection: T cells are removed from the patient's blood through a process called leukapheresis.
• Modification: In a specialized laboratory, a new gene is inserted into these T cells. This gene instructs the cells to produce a specific protein on their surface called a chimeric antigen receptor (CAR).
• Expansion: The modified T cells are grown in large numbers before being sent back to the medical facility.
• Infusion: The patient receives the modified cells back into their bloodstream through an intravenous (IV) infusion.

Targeting Cancer Cells

The chimeric antigen receptor (CAR) on the modified T cells is designed to recognize and bind to another protein called CD19. This protein is found on the surface of certain types of B-cell lymphoma cells. Once the modified T cells attach to the CD19 protein, they are activated to kill the cancer cells and may continue to multiply in the body to provide ongoing defense.

Common Side Effects

Many people experience side effects during or after treatment with Yescarta. Common side effects may include:

• Fever and chills
• Fatigue or extreme tiredness
• Nausea, diarrhea, or constipation
• Headache and dizziness
• Muscle or joint pain
• Cough or shortness of breath
• Fast heartbeat
• Decreased appetite

Serious Side Effects

Yescarta can cause serious complications that need to be monitored closely by a healthcare provider. These may include:

• Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause high fever, low blood pressure, and difficulty breathing.
• Neurologic Toxicities: Problems with the brain or nervous system, such as confusion, tremors, seizures, or difficulty speaking and understanding speech.
• Severe Infections: An increased risk of developing life-threatening bacterial, viral, or fungal infections.
• Low Blood Cell Counts: A significant drop in white blood cells, red blood cells, or platelets, which can increase the risk of infection, fatigue, or bleeding.
• Hypogammaglobulinemia: Low levels of antibodies in the blood, which may require supplemental treatment to help fight infections.

Boxed Warnings

Yescarta has boxed warnings for two major risks: cytokine release syndrome (CRS) and neurological toxicities. Both conditions can be severe or life-threatening.

Cytokine Release Syndrome (CRS)

CRS is a systemic inflammatory response that occurs when the engineered immune cells become highly active. Symptoms often include high fever, chills, low blood pressure, and low oxygen levels. Most cases occur within the first week after infusion. Healthcare providers monitor patients daily for at least seven days following treatment at a certified facility.

Neurological Toxicities

Serious neurological side effects can occur, sometimes alongside CRS or after it has resolved. These may include confusion, tremors, seizures, loss of consciousness, or difficulty speaking. Due to the risk of sudden neurological changes, patients are advised not to drive or operate heavy machinery for at least eight weeks after receiving the infusion.

REMS Program

Because of the risks of CRS and neurological toxicities, Yescarta is only available through a restricted program called the Yescarta REMS (Risk Evaluation and Mitigation Strategy). This program ensures that the drug is only dispensed to certified hospitals and clinics that have specialized training and immediate access to emergency treatments for these reactions.

Infections and Low Blood Counts

Treatment can lead to severe or life-threatening infections. Healthcare providers will monitor for signs of fever or other symptoms of infection. Additionally, many patients experience prolonged cytopenia, which is a significant and lasting drop in white blood cells, red blood cells, or platelets. This can increase the risk of bleeding or further infection for several weeks or months after the infusion.

Other Precautions

• Hypogammaglobulinemia: Yescarta may cause a decrease in the level of antibodies (immunoglobulins) in the blood. This condition can last for a long time and may require supplemental antibody treatments to help prevent infections.
• Secondary Malignancies: As with other gene therapies, there is a potential risk of developing new types of cancers later in life. Patients are typically monitored long-term for this risk.
• Vaccinations: Live virus vaccines should be avoided before and during treatment, as the immune system may not be able to handle the vaccine safely.
• Hypersensitivity: Severe allergic reactions can occur during the infusion process. Patients are monitored closely for signs of hypersensitivity.

Pregnancy

It is not known if Yescarta can cause harm to an unborn baby, as there are no clinical studies involving pregnant women. However, because of the way Yescarta works in the body, it could potentially cause a decrease in B-cells (a type of white blood cell) in the fetus.

Key considerations for pregnancy include:

• Pregnancy Testing: Healthcare providers typically require a negative pregnancy test for individuals of reproductive potential before starting the treatment process.
• Contraception: Patients should discuss the use of effective birth control with their doctor to prevent pregnancy during and after treatment.

Breastfeeding

There is no information available on whether Yescarta passes into human breast milk or how it might affect a nursing infant. Because the risks are unknown, patients should discuss the benefits and risks of breastfeeding with their healthcare team while undergoing treatment.

Dosage Forms

Yescarta is available as a cell suspension for intravenous infusion. It is a personalized treatment created from a patient's own T cells, which are a type of white blood cell.

Administration and Packaging

• It is supplied as a frozen suspension in an infusion bag.
• The medication is administered as an infusion into a vein.
• Each dose is prepared specifically for the individual patient.

FDA Approval and Indications

Yescarta (axicabtagene ciloleucel) is a genetically modified autologous T-cell immunotherapy. It was first approved by the U.S. Food and Drug Administration (FDA) in 2017. It is currently approved for use in adult patients with:

• Large B-cell lymphoma (LBCL) that has not responded to first-line chemoimmunotherapy or has returned within 12 months of that treatment.
• Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma.
• Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

Boxed Warning and Safety Requirements

The FDA has issued a Boxed Warning for Yescarta because it can cause serious or life-threatening side effects, including:

• Cytokine Release Syndrome (CRS): A severe systemic inflammatory response that can cause high fever and organ dysfunction.
• Neurologic Toxicities: Serious brain-related side effects such as confusion, seizures, or altered consciousness.

Due to these risks, the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for Yescarta. This restricted program ensures that the medication is only administered at certified healthcare facilities that are specially trained to monitor for and manage these severe reactions. These facilities must have immediate access to specific medications, such as tocilizumab, to treat cytokine release syndrome.

Factors Influencing Cost

The cost of Yescarta is high because it is a personalized gene therapy. The treatment involves collecting a patient's own T cells, genetically engineering them in a laboratory, and then infusing them back into the patient. This one-time treatment requires significant resources and specialized facilities.

Additional Treatment Costs

The total cost of care often exceeds the price of the drug itself. Additional expenses typically include:

• Hospitalization for the infusion and the mandatory monitoring period afterward.
• Management of potential side effects, such as cytokine release syndrome or neurological toxicities.
• Travel and lodging expenses if the patient does not live near an authorized treatment center.

Insurance and Financial Assistance

Most insurance providers, including Medicare and Medicaid, offer coverage for Yescarta when it is used for FDA-approved indications. However, patients often need prior authorization before treatment begins. The manufacturer may provide financial assistance programs or support services to help patients manage out-of-pocket costs and navigate insurance requirements.